News

Gene Therapy Stocks Fall as FDA Pushes Out Another Top Regulator
The HHS said center directors deserve to be supported by managers aligned with aggressive goals “to expeditiously advance ...
STAT21h
FDA’s gene therapy turmoil, and an alternative model for funding research
We look at the continued turmoil within the FDA, including the forced dismissal of top gene therapy regulator Nicole Verdun, ...
FDA cell and gene therapy director exit increases ‘volatility’ for sector
Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...
BioPharma Dive2h
Gene therapy faces fresh uncertainty as two more top FDA officials depart
The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...
Fierce Biotech10h
Industry ‘deeply disappointed’ as FDA puts cell and gene therapy chief on administrative leave
The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...
Investor's Business Daily on MSN1h
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.
Medical Marketing & Media4h
Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more
AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.
Newseria BIZNES10h
Japan Gene Therapy Market Growth: $148.06M in 2024 to $904.94M by 2033 | CAGR 20.3%
Japan's Gene Therapy Market is set to grow from $148.06M in 2024 to $904.94M by 2033, driven by innovation and a strong CAGR of 20.3% during 2025–2033. The Japan Gene Therapy Market is witnessing ...